Menu

Filtros : "Financiamento FAPESP" "NEOPLASIAS" "Future Medicinal Chemistry" Limpar

Filtros

Refine with date range

  • 1

1 - 2 (2 records)

  • Artigo de periodico

    Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception (2025)

    Giarolla, Jeanine ; Holdaway, Kelsey A ; Nazari, Maryam; Aiad, Laila; Sarkar, Bidisha; Georg, Gunda I

    Source: Future Medicinal Chemistry. Unidade: FCF

    Subjects: LIGANTES, NEOPLASIAS, ENSAIO CLÍNICO, LIGANTES

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      GIAROLLA, Jeanine et al. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception. Future Medicinal Chemistry, v. 17, n. 5, p. 607–627, 2025Tradução . . Disponível em: https://dx.doi.org/10.1080/17568919.2025.2463868. Acesso em: 08 out. 2025.

    • APA

      Giarolla, J., Holdaway, K. A., Nazari, M., Aiad, L., Sarkar, B., & Georg, G. I. (2025). Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception. Future Medicinal Chemistry, 17( 5), 607–627. doi:10.1080/17568919.2025.2463868

    • NLM

      Giarolla J, Holdaway KA, Nazari M, Aiad L, Sarkar B, Georg GI. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception [Internet]. Future Medicinal Chemistry. 2025 ; 17( 5): 607–627.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2025.2463868

    • Vancouver

      Giarolla J, Holdaway KA, Nazari M, Aiad L, Sarkar B, Georg GI. Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception [Internet]. Future Medicinal Chemistry. 2025 ; 17( 5): 607–627.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2025.2463868

  • Artigo de periodico-carta/editorial

    SETDB1: an emerging target for anticancer drug development [Editorial] (2025)

    Trossini, Gustavo Henrique Goulart ; Hassanie, Haifa ; Penteado, André Berndt ; Hajje, Marissa El

    Source: Future Medicinal Chemistry. Unidade: FCF

    Subjects: NEOPLASIAS, PLANEJAMENTO DE FÁRMACOS

    PrivadoAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      TROSSINI, Gustavo Henrique Goulart et al. SETDB1: an emerging target for anticancer drug development [Editorial]. Future Medicinal Chemistry. London: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: https://dx.doi.org/10.1080/17568919.2024.2444869. Acesso em: 08 out. 2025. , 2025

    • APA

      Trossini, G. H. G., Hassanie, H., Penteado, A. B., & Hajje, M. E. (2025). SETDB1: an emerging target for anticancer drug development [Editorial]. Future Medicinal Chemistry. London: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. doi:10.1080/17568919.2024.2444869

    • NLM

      Trossini GHG, Hassanie H, Penteado AB, Hajje ME. SETDB1: an emerging target for anticancer drug development [Editorial] [Internet]. Future Medicinal Chemistry. 2025 ;( 2): 153–155.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2024.2444869

    • Vancouver

      Trossini GHG, Hassanie H, Penteado AB, Hajje ME. SETDB1: an emerging target for anticancer drug development [Editorial] [Internet]. Future Medicinal Chemistry. 2025 ;( 2): 153–155.[citado 2025 out. 08 ] Available from: https://dx.doi.org/10.1080/17568919.2024.2444869
  • 1

1 - 2 (2 records)

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2025